Business Context and Reporting Period
This Form 6-K filing by Enlivex Therapeutics Ltd. covers the month of October 2019. The report discloses a significant corporate governance change: the appointment of Dr. Oren Hershkovitz as Chief Executive Officer, effective November 16, 2019. Dr. Schmuel Hess will serve as CEO until that transition date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and appointment details rather than financial performance.
Material Changes
- Executive Leadership: Dr. Oren Hershkovitz is appointed CEO, replacing Dr. Schmuel Hess on November 16, 2019.
- Compensation Package: Dr. Hershkovitz will receive an annual salary of NIS 65,000 and options to purchase 150,000 ordinary shares vesting over four years.
- Related Party Transactions: The Company confirmed no transactions exceeding $120,000 involving Dr. Hershkovitz since the beginning of the last fiscal year.
Outlook and Risks
The filing does not contain specific financial guidance, market outlook, or new risk factors. It notes that Dr. Hershkovitz brings extensive experience in global pharmaceutical program development from preclinical through Phase 3 trials, having previously served as General Manager at OPKO Biologics, Ltd. The report is incorporated by reference into the Company's registration statements on Forms S-8 and F-3.
Key Facts for Investor Verification
- Confirm the exact start date of Dr. Hershkovitz's tenure (November 16, 2019) and the transition plan from Dr. Hess.
- Verify the vesting schedule and strike price details for the 150,000 share options granted to Dr. Hershkovitz.
- Review the Company's Form 20-F (filed April 30, 2019) for standard executive benefits applicable to Dr. Hershkovitz.
- Monitor future filings for the impact of this leadership change on the Company's clinical development pipeline.